Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 44/74 ]
NASDAQ | Common Stock
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.
It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.
The company is based in Houston, Texas.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Sep 30, 23 | -0.31 Decreased by -932.67% | - |
Jun 30, 23 | -0.11 Decreased by -88.17% | - |
May 10, 23 | -0.10 Decreased by -25.00% | - |
Mar 27, 23 | -0.10 Decreased by -66.67% | - |
Nov 10, 22 | -0.03 | - |
Sep 19, 22 | -0.06 | - |
May 31, 22 | -0.08 | - |
Jan 4, 22 | -0.06 | - |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 23 | 24.11 K Decreased by -95.58% | -2.30 M Decreased by -1.60 K% | Decreased by -9.53 K% Decreased by -38.31 K% |
Jun 30, 23 | 35.54 K Decreased by -91.42% | -822.44 K Decreased by -89.56% | Decreased by -2.31 K% Decreased by -2.11 K% |
Mar 31, 23 | 30.56 K Decreased by -90.55% | -709.64 K Decreased by -72.50% | Decreased by -2.32 K% Decreased by -1.73 K% |
Dec 31, 22 | 38.42 K Increased by +60.11% | -752.25 K Decreased by -26.23% | Decreased by -1.96 K% Increased by +21.16% |
Sep 30, 22 | 545.32 K Increased by +874.31% | -135.27 K Increased by +92.48% | Decreased by -24.80% Increased by +99.23% |
Jun 30, 22 | 414.29 K Increased by +1.32 K% | -433.88 K Increased by +79.34% | Decreased by -104.73% Increased by +98.55% |
Mar 31, 22 | 323.32 K Increased by +825.28% | -411.38 K Increased by +74.01% | Decreased by -127.24% Increased by +97.19% |
Dec 31, 21 | 24.00 K - | -595.93 K - | Decreased by -2.48 K% - |